Related Experiment Video
Updated: Jan 13, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Probiotic Supplementation With Bifidobacterium longum Subsp. Longum BL21 Improves Glycemic Control and Modulates Gut
Chengsheng Zhu1, Yinhua Liu1, Yanyan Chen1
1College of Food Science and Technology Henan University of Technology Zhengzhou China.
Abstract:
Type 2 diabetes mellitus (T2DM) remains a major global health challenge, with emerging evidence highlighting the therapeutic potential of gut microbiota modulation. This study aimed to evaluate the efficacy and safety of Bifidobacterium longum subsp. longum BL21 as an adjunctive therapy to metformin in patients with T2DM. In this 12-week, randomized, double-blind, placebo-controlled trial, patients with T2DM received either metformin plus BL21 or metformin plus placebo. The primary endpoint was the change in hemoglobin A1c (HbA1c), while secondary endpoints included changes in fasting blood glucose (FBG), insulin resistance, lipid profiles, and gut microbiota composition. Supplementation with BL21 led to a significant reduction in HbA1c levels (p = 0.026) compared with placebo. Non-significant trends toward reduction were also observed for FBG and insulin resistance. The intervention was well tolerated, with a safety profile comparable to placebo. Gut microbiota analysis revealed an increase in beneficial genera, including Bifidobacterium and Faecalibacterium, alongside a reduction in pathogenic taxa in the BL21 group. As an adjunct to metformin, BL21 supplementation improved glycemic control and modulated gut microbiota in patients with T2DM. These findings support the potential of BL21 as a novel adjunctive strategy for T2DM management, warranting further validation in larger and longer-term studies. Clinical Trial Registration Number: ChiCTR2300073299.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Biguanides and Glitazones

